Method for generating primate cardiovascular progenitor cells for clinical use from primate embryonic stem cells or embryonic-like state cells, and their applications

US8361796B2 · kind B2 · utility

Assignees

• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• UNIVERSITE DE PARIS DESCARTES · FR
• UNIVERSITÉ PARIS DIDEROT—PARIS 7 · FR

Inventors

• Philippe Menasche · Paris, FR
• Michel Puceat · Mennecy, FR
• Jérôme Larghero · Boulogne-Billancourt, FR
• Guillaume Alexandre Blin · Carlisle, US
• David Nury · Corbeil, FR
• Sonia Stefanovic · Draveil, FR

Key dates

• Filing date: Mar 10, 2009
• Grant date: Jan 29, 2013
• Expiry date: Apr 11, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2506/45
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEAI) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods or product obtainable by the claimed methods form also part of the present invention.